Beijing Strong Biotechnologies, Inc.

bsbe.com.cn

Beijing Strong Biotechnologies, Inc. (BSBE) is one of the leading Chinese biotechnology companies. Since its establishment in June, 1988 by several Ph. D graduates from the Chinese Academy of Sciences, BSBE is now one of the fastest growing companies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact, Medical

OMEGA THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT TO EVALUATE THE COMBINATION OF OTX-2002 AND ATEZOLIZUMAB IN HEPATOCELLULAR CARCINOMA

Globenewswire | March 31, 2023

news image

Omega Therapeutics, Inc. a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today announced a clinical supply agreement with Roche to evaluate OTX-2002, its lead candidate in development for the treatment of MYC-driven hepatocellular carcinoma (HCC), in combination with Roche’s anti-PD-L1 therapy, atezolizumab, as part of Omega’s Phase 1/2 MYCHELANGELO™ I clinical trial. “This agreem...

Read More

Cell and Gene Therapy

VIPERGEN PUBLISHES POWERFUL NEW DRUG DISCOVERY APPROACH FOR THE FIRST TIME, SCREENING DNA-ENCODED SMALL-MOLECULE LIBRARIES (DELS) INSIDE LIVING CELLS

Vipergen | February 18, 2021

news image

Vipergen ApS announced today a published study depicting a ground-breaking new medication revelation approach that empowers, interestingly, screening DNA-encoded small-molecule libraries (DELs) inside living cells. The study, published in the peer-reviewed Journal of the American Chemical Society, highlights the potential of Vipergen's Cellular Binder Trap Enrichment® (cBTE) technology to significantly grow the ability to discover novel small molecules, including against difficult-to-dru...

Read More

Cell and Gene Therapy

GENSCRIPT AND GLADSTONE-UCSF INSTITUTE OF GENOMIC IMMUNOLOGY COLLABORATE ON GROUNDBREAKING NON-VIRAL CELL THERAPY STUDY

Genscript Biotech Corporation | September 23, 2022

news image

GenScript USA Inc., the world's leading life-science research tools and services provider, is collaborating with researchers at the Gladstone-UCSF Institute of Genomic Immunology to advance the development of new, non-viral cell therapies that modify genomic sequences in the pursuit of more effective cell therapy products while limiting the cellular toxicity that is typically associated with previously available methods. A new study, published in Nature Biotechnology, details ...

Read More

Medical

NANOFORM LAUNCHES TECHNOLOGY THAT CAN FORM BIOLOGICAL NANOPARTICLES AS SMALL AS 50 NM AND NEW NEAR-TERM BUSINESS TARGET FOR 2021

Nanoform | November 27, 2020

news image

Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medication empowering organization, today reported a proprietary technology that can frame biological nanoparticles as small as 50 nm and declared another close term business focus for 2021 to convey its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner. As drug molecules become more complex so do the alternatives to convey them. This complex nanoparticle...

Read More
news image

Industrial Impact, Medical

OMEGA THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT TO EVALUATE THE COMBINATION OF OTX-2002 AND ATEZOLIZUMAB IN HEPATOCELLULAR CARCINOMA

Globenewswire | March 31, 2023

Omega Therapeutics, Inc. a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today announced a clinical supply agreement with Roche to evaluate OTX-2002, its lead candidate in development for the treatment of MYC-driven hepatocellular carcinoma (HCC), in combination with Roche’s anti-PD-L1 therapy, atezolizumab, as part of Omega’s Phase 1/2 MYCHELANGELO™ I clinical trial. “This agreem...

Read More
news image

Cell and Gene Therapy

VIPERGEN PUBLISHES POWERFUL NEW DRUG DISCOVERY APPROACH FOR THE FIRST TIME, SCREENING DNA-ENCODED SMALL-MOLECULE LIBRARIES (DELS) INSIDE LIVING CELLS

Vipergen | February 18, 2021

Vipergen ApS announced today a published study depicting a ground-breaking new medication revelation approach that empowers, interestingly, screening DNA-encoded small-molecule libraries (DELs) inside living cells. The study, published in the peer-reviewed Journal of the American Chemical Society, highlights the potential of Vipergen's Cellular Binder Trap Enrichment® (cBTE) technology to significantly grow the ability to discover novel small molecules, including against difficult-to-dru...

Read More
news image

Cell and Gene Therapy

GENSCRIPT AND GLADSTONE-UCSF INSTITUTE OF GENOMIC IMMUNOLOGY COLLABORATE ON GROUNDBREAKING NON-VIRAL CELL THERAPY STUDY

Genscript Biotech Corporation | September 23, 2022

GenScript USA Inc., the world's leading life-science research tools and services provider, is collaborating with researchers at the Gladstone-UCSF Institute of Genomic Immunology to advance the development of new, non-viral cell therapies that modify genomic sequences in the pursuit of more effective cell therapy products while limiting the cellular toxicity that is typically associated with previously available methods. A new study, published in Nature Biotechnology, details ...

Read More
news image

Medical

NANOFORM LAUNCHES TECHNOLOGY THAT CAN FORM BIOLOGICAL NANOPARTICLES AS SMALL AS 50 NM AND NEW NEAR-TERM BUSINESS TARGET FOR 2021

Nanoform | November 27, 2020

Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medication empowering organization, today reported a proprietary technology that can frame biological nanoparticles as small as 50 nm and declared another close term business focus for 2021 to convey its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner. As drug molecules become more complex so do the alternatives to convey them. This complex nanoparticle...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us